Lung Cancer
Volume 69, Issue 3 , Pages 302-306 , September 2010

Pemetrexed and cisplatin with concurrent radiotherapy for locally advanced non-small cell and limited disease small cell lung cancer: Results from 2 phase I studies

  • V. Surmont

      Affiliations

    • Department of Respiratory Medicine, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32 9 332 1530; fax: +32 9 332 2341.
    • ,
  • E.F. Smit

      Affiliations

    • Department of Pulmonology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    • ,
  • M. de Jonge

      Affiliations

    • Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    • ,
  • J.G. Aerts

      Affiliations

    • Department of Pulmonology, Amphia Hospital, Breda, The Netherlands
    • ,
  • K. Nackaerts

      Affiliations

    • Department of Pulmonology, University Hospital Gasthuisberg, Leuven, Belgium
    • ,
  • R. Vernhout

      Affiliations

    • Department of Trials and Statistics, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    • ,
  • J. Gras

      Affiliations

    • Department of Trials and Statistics, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    • ,
  • A. Van Wijk

      Affiliations

    • Department of Pulmonology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    • ,
  • E.C.J. Phernambucq

      Affiliations

    • Department of Pulmonology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    • ,
  • J.P. van Meerbeeck

      Affiliations

    • Department of Respiratory Medicine, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium
    • ,
  • S. Senan

      Affiliations

    • Department of Radiation Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    • ,
  • C.J. Kraaij

      Affiliations

    • Eli Lilly, Houten, The Netherlands
    • ,
  • N. Chouaki

      Affiliations

    • Eli Lilly France, Paris, France
    • ,
  • J. Praag

      Affiliations

    • Department of Radiation Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    • ,
  • R.J. van Klaveren

      Affiliations

    • Department of Pulmonology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

Received 9 September 2009 ,Revised 1 December 2009 ,Accepted 5 December 2009.

References 

  1. Aupérin A, Le Péchoux C, Pignon JP, Koning C, Jeremic B, Clamon G, et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol. 2006;17:473–483
  2. Machtay M, Hsu C, Komaki R, Sause W, Swann R, Langer C, et al. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the radiation therapy oncology group (RTOG) experience. Int J Radiat Oncol Biol Phys. 2005;63:667–671
  3. Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small cell lung cancer. A meta-analysis. Cancer. 1995;76:593–601
  4. Schild SE, Wong WW, Vora SA, Halyard M, Northfelt D, Kogut H, et al. The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2005;62:1432–1437
  5. West H, Albain KS. Current standards and ongoing controversies in the management of locally advanced non-small cell lung cancer. Semin Oncol. 2005;32(3):284–292
  6. Kim YS, Yoon SM, Choi EK, Yi BY, Kim JH, Ahn SD, et al. Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for stage IIIB non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2005;62:76–81
  7. Cohen EE, Vokes EE. Induction chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. Hematol Oncol Clin North Am. 2004;18:81–90
  8. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992;10(6):890–899
  9. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327(23):1618–1624
  10. Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002;20:3054–3060
  11. Turrisi AT, Kim K, Blum R, Sause WT, Livingstone RB, Komaki R, et al Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340(4):265–271
  12. Turrisi AT. Limited-disease small-cell lung cancer research: sense and nonsense. Int J Radiat Oncol Biol Phys. 2004;59(4):925–927
  13. Murray N, Coy P, Pater JL, Hodson I, Arnold A, Zee BC, et al. Importance of timing for thoracic radiotherapy in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1993;11(2):336–344
  14. Shih C, Chen VJ, Gossett LS, Gates SB, Mackellar WC, Habeck LL, et al. LY231514, a pyrrolo (2,3-d) pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997;57:1116–1123
  15. Adjei AA. Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther. 2003;3:145–156
  16. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, Von Pawel J, et al. Randomized phase II trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–1597
  17. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644
  18. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Van Steenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(July (21)):3543–3551
  19. Bischof M, Weber KJ, Blatter J, Wannenmacher M, Latz D, et al. Interaction of pemetrexed (Alimta, multi-targeted antifolate) and irradiation in vitro. Int J Radiat Oncol Biol Phys. 2002;52(April (5)):1381–1388
  20. Seiwert TY, Connell P, Mauer AM, Hoffmann PC, George CM, Szeto L, et al. Phase I study of pemetrexed, carboplatin and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res. 2007;13(2):515–522
  21. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99(11):847–850
  22. International Commission on Radiation Units Measurements . ICRU Report 50: prescribing, recording and reporting photon beam therapy. Report 50. Oxford, UK: University of Oxford Press; 1993;
  23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–216
  24. Socinski MA, Smit EF, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin (PC) versus etoposide plus carboplatin (EC) in chemonaive patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC): interim results. 2008 ASCO Meeting.
  25. Brade A, Bezjak A, MacRae , et al. A phase I study of concurrent pemetrexed (P)/cisplatin (C)/radiation (RT) for unresectable stage IIIA/B non-small cell lung cancer (NSCLC). J Clin Oncol. 2008;26(20 Suppl.):(abstr 7550)
  26. Gadjeel SM, Ruckdeschel JC, Wozniak A, et al. Pemetrexed and cisplatin with concurrent thoracic radiation therapy (TRT) followed by docetaxel in stage III non-small-cell lung cancer (NSCLC) patients. J Clin Oncol. 2008;26(20 Suppl.):(abstr 7569)
  27. Jalal S, Ansari R, Govindan R, Bhatia S, Bruetmen D, Fisher W, et al. Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study. Thorac Oncol. 2009;4(January (1)):93–96
  28. Eismann U, Oberschmidt O, Ehnert M, et al. Thymidylate synthase gene expression in solid tumors predicts for response to pemetrexed in vitro. J Clin Oncol. 2006;24(18S):13058;[ASCO Annual Meetings Proceedings]
  29. Ceppi P, Volante M, Ferrero A, Righi L, Rapa I, Rosas R, et al. Thymidylate synthase expression in gastropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res. 2008;14:1059–1064

PII: S0169-5002(09)00637-0

doi: 10.1016/j.lungcan.2009.12.001

Lung Cancer
Volume 69, Issue 3 , Pages 302-306 , September 2010

Article Tools